MedTrace Logo

Bioequivalence Study in Healthy Volunteers

NCT00387985 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-11-25

No results posted yet for this study

Summary

Primary: To determine the bioequivalence between the new formulation and the current formulation of the investigational drug, MOA-728.

Conditions

  • Healthy

Interventions

DRUG

MOA-728

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff Cohn · Bausch Health Americas, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387985 on ClinicalTrials.gov